Advances on inhalation therapy for occupational pneumoconiosis combined with chronic obstructive pulmonary disease
10.20001/j.issn.2095-2619.20251018
- VernacularTitle:职业性尘肺病合并慢性阻塞性肺疾病吸入治疗研究进展
- Author:
Jingzheng JIANG
1
;
Jiabin CHEN
;
Qifeng WU
;
Jifeng LI
;
Bingling CHEN
Author Information
1. The Second People's Hospital of Shantou, Shantou, Guangdong 515000, China
- Publication Type:Journal Article
- Keywords:
Pneumoconiosis;
Chronic obstructive pulmonary disease;
Inhalation therapy;
Inhaler devices;
Bronchodilators;
Research progress
- From:
China Occupational Medicine
2025;52(5):585-588
- CountryChina
- Language:Chinese
-
Abstract:
The lung function of patients with occupational pneumoconiosis (hereinafter referred to as "pneumoconiosis") combined with chronic obstructive pulmonary disease (COPD) declines rapidly. Inhaled pharmacotherapy is crucial in the treatment of patients with pneumoconiosis combined with COPD. At present, pressurized metered-dose inhalers, dry powder inhalers, and soft mist inhalers are commonly used to deliver bronchodilators (including long-acting β2-adrenergic agonists, long-acting muscarinic antagonists, or their fixed-dose combinations) in inhaled pharmacotherapy. Peak inspiratory flow (PIF) is a commonly used indicator for evaluating the effectiveness of inhalation therapy. Patients with good coordination of hand and mouth, and a high PIF (≥30 L/min) can be treated with pressurized metered-dose inhalers or dry powder inhalers, whereas patients with poor coordination or insufficient PIF (<30 L/min) should be treated with pressurized metered-dose inhalers combined with a spacer or with nebulizers. In addition, the effectiveness of inhalation therapy is affected by individual factors, such as treatment adherence and pulmonary function, as well as drug-related factors, including the use of inhaled corticosteroids and the selection of bronchodilators. Inhaled pharmacotherapy appears to have substantial potential in the treatment of pneumoconiosis complicated with COPD. Future efforts should focus on the development of more effective inhaled drugs with fewer adverse effects and more user-friendly inhalation devices, as well as on optimizing inhalation treatment regimens to enable precision therapy and improve therapeutic efficacy.
